Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|June 19, 2019

IVERIC bio, Catalent Partner on Gene Therapy for Orphan Inherited Retinal Diseases

IVERIC bio and Catalent Biologics have entered into a strategic manufacturing agreement for gene therapy product candidates to treat orphan inherited retinal diseases.

In a June 17, 2019 press statement, IVERIC bio and Catalent Biologics have announced they have entered into a strategic manufacturing agreement for the production and manufacture of GMP-grade adeno-associated virus (AAV) vector for IVERIC bio’s gene therapy product candidates to treat orphan inherited retinal diseases.

Under the terms of the agreement, IVERIC bio has employed Paragon Gene Therapy, which is a part of Catalent Biologics, to provide materials for preclinical activities and the planned Phase I/II clinical trials for IC-100-which is aimed at treating rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP)-and IC-200-for the treatment of BEST1 related retinal diseases.

“We fully appreciate the importance of having a world-class manufacturing infrastructure in place as we continue to build and advance our gene therapy pipeline for inherited retinal diseases,” said Glenn P. Sblendorio, chief executive officer and president of IVERIC bio. “Our relationship with Catalent secures access to manufacturing capabilities and capacity that we believe will enable us to enter into the next phase of gene therapy development with our product candidates IC-100 for RHO-adRP and IC-200 for BEST1 related retinal diseases.”

“We are extremely pleased to partner with IVERIC bio as they advance their portfolio of AAV gene therapies for orphan inherited retinal diseases,” added Pete Buzy, president of Paragon Gene Therapy. “We look forward to a strong relationship with the goal of achieving IVERIC bio’s gene therapy AAV manufacturing milestones for the production of clinical material.”

Source: Catalent

 


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.